文献速递帕金森病与运动障碍

LRRK2 p.Gly2019Ser帕金森病发病年龄跨祖先与国家的差异

The Age at Onset of LRRK2 p.Gly2019Ser Parkinson's Disease Across Ancestries and Countries of Origin.
PubMed 文献 · Ann Neurol · 2026-02-24

本研究纳入922名无关的LRRK2 p.Gly2019Ser变异携带者,采用Cox比例风险模型分析不同祖先和国家间帕金森病累积发病率的差异。结果显示北非祖先发病年龄较欧洲祖先早5年,而德系犹太人祖先较欧洲祖先晚5年;以色列和突尼斯患者较美国患者发病年龄分别早5年和10年。遗传祖先和国家来源与LRRK2-PD发病年龄相关,提示遗传与环境因素共同影响。

要点

  • 北非祖先LRRK2-PD发病年龄较欧洲祖先早5年(HR=1.48)。
  • 德系犹太人祖先发病年龄较欧洲祖先晚5年(HR=0.61)。
  • 以色列和突尼斯患者较美国患者发病年龄分别早5年和10年。

核心结论

  • 遗传祖先和国家来源与LRRK2 p.Gly2019Ser相关帕金森病的发病年龄相关,提示遗传和环境因素均可能影响发病年龄。

研究设计与样本

  • 研究纳入922名无关的p.Gly2019Ser变异携带者( affected=762,unaffected=160),来自全球帕金森遗传学项目(GP2)及以色列德系犹太人和突尼斯阿拉伯-柏柏尔人群队列,采用Cox比例风险模型分析,所有分析均校正生物学性别,为探索性分析。

主要发现

  • 北非祖先LRRK2-PD中位发病年龄较欧洲祖先早5年(HR=1.48,95%CI=1.18-1.86,p=7.0×10^-4)。
  • 德系犹太人祖先中位发病年龄较欧洲祖先晚5年(HR=0.61,95%CI=0.50-0.75,p=4.0×10^-6)。
  • 以色列患者较美国患者中位发病年龄早5年(HR=1.59,95%CI=1.30-1.39,p=4.0×10^-6)。
  • 突尼斯患者较美国患者中位发病年龄早10年(HR=2.57,95%CI=2.16-3.06,P<2.0×10^-16)。
  • 仅分析德系犹太人背景个体时,以色列患者仍较美国患者发病年龄早(HR=1.82,95%CI=1.48-2.24,p=1.5×10^-8);仅分析美国患者时,德系犹太人祖先仍较欧洲祖先发病年龄晚(HR=0.51,95%CI=0.39-0.67,p=1.3×10^-6)。

临床怎么用

  • 在遗传咨询和临床评估中,应考虑LRRK2 p.Gly2019Ser携带者的遗传祖先和国家来源对发病年龄的潜在影响。

局限性

  • 研究为探索性分析,未报告其他局限性信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The objective of this study was to elucidate differences in the cumulative incidence of Leucine-rich repeat kinase 2 (LRRK2) p.Gly2019Ser-related Parkinson's disease (PD; LRRK2-PD) between ancestries and countries. METHODS: We included 922 unrelated p.Gly2019Ser variant carriers (affected = 762 and unaffected = 160) from the Global Parkinson's Genetics Program (GP2) in addition to cohorts recruited from the Israeli Ashkenazi Jewish and Tunisian Arab-Berber population. Cox proportional hazard models were applied to examine differences in cumulative incidence across ancestry groups and countries. All analyses were adjusted for biological sex and were exploratory. RESULTS: The median age at onset (AAO) of LRRK2-PD was 5 years younger in the North African (hazard ratio [HR] = 1.48, 95% confidence interval [CI] = 1.18-1.86, p = 7.0 × 10-4) compared with the European ancestry group. In contrast, the median AAO was 5 years older in the Ashkenazi Jewish (HR = 0.61, 95% CI = 0.50-0.75, p = 4.0 × 10-6) compared with the European ancestry group. Additionally, patients from Israel (HR = 1.59, 95% CI = 1.30-1.39, p = 4.0 × 10-6) and Tunisia (HR = 2.57, 95% CI: 2.16-3.06, P < 2.0 × 10-16) had a median 5-year and 10-year younger AAO compared with patients from the United States, respectively. Last, when focusing only on individuals with an Ashkenazi Jewish background, patients from Israel still had a younger AAO than those from the United States (HR = 1.82, 95% CI = 1.48-2.24, p = 1.5 × 10-8). Analogously, assessing only patients from the United States, the Ashkenazi Jewish ancestry group still had an older AAO than the European ancestry group (HR = 0.51, 95% CI = 0.39-0.67, p = 1.3 × 10-6). INTERPRETATION: Our results provide evidence that a person's genetic ancestry and country of origin are associated with the AAO of LRRK2-PD. This highlights the potential impact of both genetic and environmental factors on LRRK2-PD AAO. ANN NEUROL 2026;99:1394-1404.

来源:Ann Neurol,查看原文。版权归原作者所有。

引用

  1. Lüth T, Laabs BH, Sendel S, et al. The Age at Onset of LRRK2 p.Gly2019Ser Parkinson's Disease Across Ancestries and Countries of Origin. Ann Neurol. 2026. PMID: 41735653. doi:10.1002/ana.78181

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。